



UNIVERSITY OF LEEDS

This is a repository copy of *The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.*

White Rose Research Online URL for this paper:
<http://eprints.whiterose.ac.uk/102966/>

Version: Accepted Version

Article:

Cook, G orcid.org/0000-0003-0223-3652, Ashcroft, AJ, Cairns, DA orcid.org/0000-0002-2338-0179 et al. (16 more authors) (2016) The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial. *The Lancet Haematology*, 3 (7). e340-e351.

[https://doi.org/10.1016/S2352-3026\(16\)30049-7](https://doi.org/10.1016/S2352-3026(16)30049-7)

© 2016, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
<http://creativecommons.org/licenses/by-nc-nd/4.0/>

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

Subgroup	Level	HR [95%CI]	P. (het)
Patient is 65 years old or less?	Yes	0.36 (0.22, 0.59)	0.8265
	No	0.53 (0.21, 1.34)	
B2m at registration < 3.5mg/L	b2m < 3.5 mg/L	0.42 (0.24, 0.72)	0.794
	b2m >= 3.5 mg/L	0.32 (0.15, 0.70)	
Is the patients symptomatic?	Yes	0.42 (0.20, 0.86)	0.536
	No	0.35 (0.17, 0.72)	
Response as end of PAD	sCR or CR	0.19 (0.04, 0.93)	0.8425
	VGPR or PR	0.45 (0.25, 0.79)	
	SD	0.37 (0.08, 1.65)	
Previous treatment response duration was less than 24 months?	Yes	0.31 (0.12, 0.75)	0.8603
	No	0.43 (0.24, 0.80)	
Favourable FISH Cytogenetics?	Standard	0.30 (0.14, 0.65)	0.0968
	Adverse	0.47 (0.08, 2.89)	
Overall		0.37 (0.24, 0.57)	

